Skip to main content

Matthew Matasar, MD

Matthew Matasar, MD, MS
Videos
12/10/2024
Matthew Matasar, MD, discusses results from a primary analysis of the ELM-1 study that showed the encouraging efficacy and manageable safety of CD20-CD3 bispecific antibody odronextamab for relapsed/refractory DLBCL progressing after CAR...
Matthew Matasar, MD, discusses results from a primary analysis of the ELM-1 study that showed the encouraging efficacy and manageable safety of CD20-CD3 bispecific antibody odronextamab for relapsed/refractory DLBCL progressing after CAR...
Matthew Matasar, MD, discusses...
12/10/2024
Oncology
Matthew Matasar, MD
Videos
09/22/2023
Matthew Matasar, MD, discusses upcoming studies and encouraging advances in the evolving treatment landscape for patients with follicular lymphoma.
Matthew Matasar, MD, discusses upcoming studies and encouraging advances in the evolving treatment landscape for patients with follicular lymphoma.
Matthew Matasar, MD, discusses...
09/22/2023
Oncology
Matthew Matasar, MD
Videos
09/22/2023
Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma.
Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma.
Matthew Matasar, MD, shares...
09/22/2023
Oncology